Abstract

Background: Finasteride is being used to treat recurrent hematuria due to BPH. Androgen has an essential role in the production of angiogenic factors such as VEGF. Vessel density & VEGF decreases after finasteride treatment and thus improve haematospermia. Objective: To test the efficacy of finasteride to control refractory idiopathic hematospermia for which conservative treatment has failed. Methodology: This Prospective placebo-controlled study was carried out from July 2019 to June 2022 with 48 patients of hematospermia presented to the outpatient department of NIKDU. Twenty-two patients had refractory hematospermia of idiopathic nature. They were randomized into two equal groups, 11 patients in each group. One group received 5 mg finasteride daily for 3 months, and the other group received placebo. Patients were followed up with semen analysis and TRUS for 3 consecutive months and after 1 year. Result: In the finasteride-treated group, remission of hematospermia occurred in 5 patients (45%) within 1 month. Patients continued treatment for 3 months without the recurrence of hematospermia. After stopping finasteride treatment, hematospermia recurred in 3 out of 9 patients 12 months later. Two cases were not improved, but a significant decrease in frequency & amount of bleeding was observed in semen analysis. In the placebo-treated group, cessation of hematospermia occurred in 3 cases (27%) versus 9 (81%) in the finasteride group (P = 0.03) after 3 months of treatment. Conclusion: Three months of treatment with finasteride for refractory idiopathic hematospermia significantly cures hematospermia with no undesirable side effects. Bangladesh J. Urol. 2022; 25(1): 33-66

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.